Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (434)	1/9/2009 9:08:47 PM
From: rkrw	Read Replies (3) \| Respond to of 508

On the other hand they have pivotal data for pirfenidone due any day, could they be massaging the downside?

To: scaram(o)uche who wrote (434)	1/9/2009 10:45:50 PM
From: ghmm	Respond to of 508

They CC stopping the actimmune IPF trial but that was Phase 3. Don't recall a CC for the actimmune GRACES (Ovarian Cancer) that was Phase 3 too. EDIT: I just rechecked the INSPIRE failure call was actually mid March to announce restructuring and the like so the call wasn't to announce results they were released a few weeks earlier. I don't see how the trial can fail. At worst the data is mediocre perhaps there is a surprise with something (the INFORM study, animal tox issue, etc.) but I think they just want to get it out. My guess is the data is a bit better then what Telapervir has shown but nothing to make people go crazy. And Yeah I've wondered if the day are good after an initial pop if it will start being sold again. Just want to get Pirfenidone data out and move on with life :).